Low-dose methotrexate in myeloproliferative neoplasm models.
作者信息
Chinnaiya Kavitha, Lawson Michelle A, Thomas Sally, Haider Marie-Therese, Down Jenny, Chantry Andrew D, Hughes David, Green Antony, Sayers Jon R, Snowden John A, Zeidler Martin P
机构信息
The Bateson Centre, Department of Biomedical Science, The University of Sheffield, UK.
Department of Oncology & Metabolism, The University of Sheffield, UK.
出版信息
Haematologica. 2017 Sep;102(9):e336-e339. doi: 10.3324/haematol.2017.165738. Epub 2017 May 26.
Abstract
摘要
相似文献
1
Low-dose methotrexate in myeloproliferative neoplasm models.
Haematologica. 2017 Sep;102(9):e336-e339. doi: 10.3324/haematol.2017.165738. Epub 2017 May 26.
2
Low-dose methotrexate: potential clinical impact on haematological and constitutional symptoms in myeloproliferative neoplasms.
Br J Haematol. 2019 Nov;187(3):e69-e72. doi: 10.1111/bjh.16193. Epub 2019 Sep 16.
3
Ectopic PD-L1 expression in JAK2 (V617F) myeloproliferative neoplasm patients is mediated via increased activation of STAT3 and STAT5.
Hum Cell. 2020 Oct;33(4):1099-1111. doi: 10.1007/s13577-020-00370-6. Epub 2020 Jul 14.
4
Metformin exerts multitarget antileukemia activity in JAK2-positive myeloproliferative neoplasms.
Cell Death Dis. 2018 Feb 22;9(3):311. doi: 10.1038/s41419-017-0256-4.
5
HDAC8 overexpression in mesenchymal stromal cells from JAK2+ myeloproliferative neoplasms: a new therapeutic target?
Oncotarget. 2017 Apr 25;8(17):28187-28202. doi: 10.18632/oncotarget.15969.
6
Discovery and evaluation of ZT55, a novel highly-selective tyrosine kinase inhibitor of JAK2 against myeloproliferative neoplasms.
J Exp Clin Cancer Res. 2019 Feb 4;38(1):49. doi: 10.1186/s13046-019-1062-x.
7
The JAK2V617F allele burden and STAT3- and STAT5 phosphorylation in myeloproliferative neoplasms: early prefibrotic myelofibrosis compared with essential thrombocythemia, polycythemia vera and myelofibrosis.
APMIS. 2011 Aug;119(8):498-504. doi: 10.1111/j.1600-0463.2011.02754.x. Epub 2011 Apr 17.
8
Lestaurtinib (CEP701) is a JAK2 inhibitor that suppresses JAK2/STAT5 signaling and the proliferation of primary erythroid cells from patients with myeloproliferative disorders.
Blood. 2008 Jun 15;111(12):5663-71. doi: 10.1182/blood-2007-04-083402. Epub 2007 Nov 5.
9
Withacnistin inhibits recruitment of STAT3 and STAT5 to growth factor and cytokine receptors and induces regression of breast tumours.
Br J Cancer. 2014 Aug 26;111(5):894-902. doi: 10.1038/bjc.2014.349. Epub 2014 Jul 1.
10
Tetrandrine, an agonist of aryl hydrocarbon receptor, reciprocally modulates the activities of STAT3 and STAT5 to suppress Th17 cell differentiation.
J Cell Mol Med. 2017 Sep;21(9):2172-2183. doi: 10.1111/jcmm.13141. Epub 2017 Mar 22.
引用本文的文献
1
Case report: Effectiveness of low-dose methotrexate monotherapy in post-essential thrombocythemia myelofibrosis.
Front Med (Lausanne). 2024 Apr 18;11:1285772. doi: 10.3389/fmed.2024.1285772. eCollection 2024.
2
Crystal structure of the human PRPK-TPRKB complex.
Commun Biol. 2021 Feb 5;4(1):167. doi: 10.1038/s42003-021-01683-4.
3
Diminished cytokine-induced Jak/STAT signaling is associated with rheumatoid arthritis and disease activity.
PLoS One. 2021 Jan 14;16(1):e0244187. doi: 10.1371/journal.pone.0244187. eCollection 2021.
4
JAK inhibition by methotrexate (and csDMARDs) may explain clinical efficacy as monotherapy and combination therapy.
J Leukoc Biol. 2019 Nov;106(5):1063-1068. doi: 10.1002/JLB.5RU0519-145R. Epub 2019 Jul 16.
本文引用的文献
1
Design and Synthesis of a Pan-Janus Kinase Inhibitor Clinical Candidate (PF-06263276) Suitable for Inhaled and Topical Delivery for the Treatment of Inflammatory Diseases of the Lungs and Skin.
J Med Chem. 2017 Jan 26;60(2):767-786. doi: 10.1021/acs.jmedchem.6b01634. Epub 2017 Jan 4.
2
Low-dose methotrexate as treatment of myeloproliferative neoplasms: Proof of principle of clinical activity.
Am J Hematol. 2016 Aug;91(8):E329-30. doi: 10.1002/ajh.24406. Epub 2016 Jun 3.
3
Recent advances in understanding myelofibrosis and essential thrombocythemia.
F1000Res. 2016 Apr 19;5. doi: 10.12688/f1000research.8081.1. eCollection 2016.
4
Changes in quality of life and disease-related symptoms in patients with polycythemia vera receiving ruxolitinib or standard therapy.
Eur J Haematol. 2016 Aug;97(2):192-200. doi: 10.1111/ejh.12707. Epub 2016 Jan 3.
5
Methotrexate Is a JAK/STAT Pathway Inhibitor.
PLoS One. 2015 Jul 1;10(7):e0130078. doi: 10.1371/journal.pone.0130078. eCollection 2015.
6
Risk and Cause of Death in Patients Diagnosed With Myeloproliferative Neoplasms in Sweden Between 1973 and 2005: A Population-Based Study.
J Clin Oncol. 2015 Jul 10;33(20):2288-95. doi: 10.1200/JCO.2014.57.6652. Epub 2015 Jun 1.
7
Ruxolitinib versus standard therapy for the treatment of polycythemia vera.
N Engl J Med. 2015 Jan 29;372(5):426-35. doi: 10.1056/NEJMoa1409002.
8
Mechanisms of Jak/STAT signaling in immunity and disease.
J Immunol. 2015 Jan 1;194(1):21-7. doi: 10.4049/jimmunol.1401867.
9
Transient low-dose methotrexate generates B regulatory cells that mediate antigen-specific tolerance to alglucosidase alfa.
J Immunol. 2014 Oct 15;193(8):3947-58. doi: 10.4049/jimmunol.1303326. Epub 2014 Sep 10.
10
JAK2V617F homozygosity drives a phenotypic switch in myeloproliferative neoplasms, but is insufficient to sustain disease.
Blood. 2014 May 15;123(20):3139-51. doi: 10.1182/blood-2013-06-510222. Epub 2014 Apr 1.
Zotero 插件